Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.49 |
| ▸ | BRD4 | O60885 | 10/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | BRD2 | P25440 | 3/20 | 0.46 |
| ▸ | JAK3 | P52333 | 3/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570129 | 1.00 | JAK2 (0.49) | JAK2BRD4WEE1FGFR4FGFR1 | |
| SCHEMBL16570494 | 1.00 | JAK2 (0.49) | JAK2BRD4WEE1FGFR4FGFR1 | |
| SCHEMBL16570146 | 0.90 | JAK2 (0.58) | JAK2BRD4WEE1FGFR4JAK1 | |
| SCHEMBL17958738 | 0.88 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16571128 | 0.88 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16570331 | 0.88 | FGFR4 (0.56) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16570953 | 0.82 | WEE1 (0.47) | JAK2BRD4WEE1JAK1BRD2 | |
| SCHEMBL17958812 | 0.82 | WEE1 (0.47) | JAK2BRD4WEE1JAK1BRD2 | |
| SCHEMBL16570057 | 0.82 | JAK2 (0.49) | JAK2BRD4WEE1FGFR4JAK1 | |
| SCHEMBL16580972 | 0.80 | JAK2 (0.61) | JAK2BRD4WEE1FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | JAK2 9/4885BRD4 427/4885WEE1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.